KPT-276inhibitor of nuclear export (SINE) and CRM1, orally bioavailable CAS# 1421919-75-6 |
- Elacridar
Catalog No.:BCC1546
CAS No.:143664-11-3
- Elacridar hydrochloride
Catalog No.:BCC1547
CAS No.:143851-98-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1421919-75-6 | SDF | Download SDF |
PubChem ID | 71496742 | Appearance | Powder |
Formula | C16H10F8N4O | M.Wt | 426.26 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO > 10 mM | ||
Chemical Name | (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one | ||
SMILES | C1C(CN1C(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)(F)F | ||
Standard InChIKey | JCHAWRDHMUSLMM-UPHRSURJSA-N | ||
Standard InChI | InChI=1S/C16H10F8N4O/c17-14(18)6-27(7-14)12(29)1-2-28-8-25-13(26-28)9-3-10(15(19,20)21)5-11(4-9)16(22,23)24/h1-5,8H,6-7H2/b2-1- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
KPT-276 Dilution Calculator
KPT-276 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.346 mL | 11.7299 mL | 23.4599 mL | 46.9197 mL | 58.6497 mL |
5 mM | 0.4692 mL | 2.346 mL | 4.692 mL | 9.3839 mL | 11.7299 mL |
10 mM | 0.2346 mL | 1.173 mL | 2.346 mL | 4.692 mL | 5.865 mL |
50 mM | 0.0469 mL | 0.2346 mL | 0.4692 mL | 0.9384 mL | 1.173 mL |
100 mM | 0.0235 mL | 0.1173 mL | 0.2346 mL | 0.4692 mL | 0.5865 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
KPT-276, analog of KPT-185, is a selective inhibitor of nuclear export (SINE) and CRM1 [1].
Chromosomemaintenance protein 1 (CRM1) is a nuclear export receptor involved in the active transport of transcription factors, cell-cycle regulators, tumor suppressors and RNA molecules. In cancer, CRM1 is overexpression and overactive transport [1].
KPT-276 is an orally bioavailable and selective CRM1 inhibitor that irreversibly binds to CRM1 and blocks CRM1-mediated nuclear export [1]. In human multiple myeloma (MM) cell lines (HMCLs), KPT-276 irreversibly and specifically inhibited the nuclear export of XPO1, which encoded CRM1 and significantly reduced the viability of HMCLs. In bone marrow cells isolated from MM patients, KPT-276 induced apoptosis. Also, KPT-276 downregulated the expression of c-MYC, CDC25A and BRD4, which caused G1/S phase arrest [2].
In a xenograft human acute myeloid leukemia (AML) murine model, KPT-276 significantly increased the survival of mice and reduced the amount of white blood cells. Also, KPT-276 significantly reduced spleen weight and FLT3 protein expression [1]. In a xenograft MM mouse model, KPT-276 inhibited tumor growth [2].
References:
[1]. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood, 2012, 120(9): 1765-1773.
[2]. Schmidt J, Braggio E, Kortuem KM, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia, 2013, 27(12): 2357-2365.
- GZD824
Catalog No.:BCC4389
CAS No.:1421783-64-3
- Hederacoside C
Catalog No.:BCN2329
CAS No.:14216-03-6
- Sweroside
Catalog No.:BCN6219
CAS No.:14215-86-2
- LY3039478
Catalog No.:BCC2105
CAS No.:1421438-81-4
- AZ5104
Catalog No.:BCC6389
CAS No.:1421373-98-9
- AZD-9291 mesylate
Catalog No.:BCC4121
CAS No.:1421373-66-1
- AZD-9291
Catalog No.:BCC4120
CAS No.:1421373-65-0
- Mutant EGFR inhibitor
Catalog No.:BCC4119
CAS No.:1421373-62-7
- Mutated EGFR-IN-1
Catalog No.:BCC5444
CAS No.:1421372-66-8
- CYM 50769
Catalog No.:BCC6337
CAS No.:1421365-63-0
- (+)-Ketoconazole
Catalog No.:BCC4249
CAS No.:142128-59-4
- WS6
Catalog No.:BCC5566
CAS No.:1421227-53-3
- Taxumairol B
Catalog No.:BCN6940
CAS No.:142203-64-3
- 9-Dihydro-13-acetylbaccatin III
Catalog No.:BCC1315
CAS No.:142203-65-4
- Catestatin
Catalog No.:BCC5935
CAS No.:142211-96-9
- Protionamide
Catalog No.:BCC4834
CAS No.:14222-60-7
- 2'-Rhamnoechinacoside
Catalog No.:BCN8219
CAS No.:1422390-59-7
- Rauvotetraphylline A
Catalog No.:BCN7052
CAS No.:1422506-49-7
- Rauvotetraphylline B
Catalog No.:BCN7056
CAS No.:1422506-50-0
- Rauvotetraphylline C
Catalog No.:BCN7055
CAS No.:1422506-51-1
- Rauvotetraphylline D
Catalog No.:BCN7054
CAS No.:1422506-52-2
- Rauvotetraphylline E
Catalog No.:BCN7051
CAS No.:1422506-53-3
- Kenpaullone
Catalog No.:BCC7047
CAS No.:142273-20-9
- Shizukaol B
Catalog No.:BCN6983
CAS No.:142279-40-1
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.[Pubmed:23752175]
Leukemia. 2013 Dec;27(12):2357-65.
RNA interference screening identified XPO1 (exportin 1) among the 55 most vulnerable targets in multiple myeloma (MM). XPO1 encodes CRM1, a nuclear export protein. XPO1 expression increases with MM disease progression. Patients with MM have a higher expression of XPO1 compared with normal plasma cells (P<0.04) and to patients with monoclonal gammopathy of undetermined significance/smoldering MM (P<0.0001). The highest XPO1 level was found in human MM cell lines (HMCLs). A selective inhibitor of nuclear export compound KPT-276 specifically and irreversibly inhibits the nuclear export function of XPO1. The viability of 12 HMCLs treated with KTP-276 was significantly reduced. KPT-276 also actively induced apoptosis in primary MM patient samples. In gene expression analyses, two genes of probable relevance were dysregulated by KPT-276: cell division cycle 25 homolog A (CDC25A) and bromodomain-containing protein 4 (BRD4), both of which are associated with c-MYC pathway. Western blotting and reverse transcription-PCR confirm that c-MYC, CDC25A and BRD4 are all downregulated after treatment with KPT-276. KPT-276 reduced monoclonal spikes in the Vk*MYC transgenic MM mouse model, and inhibited tumor growth in a xenograft MM mouse model. A phase I clinical trial of an analog of KPT-276 is ongoing in hematological malignancies including MM.